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Abstract: Circulating Tumor Cells (CTC) are rare cells originated from tumors that travel 
into the blood stream, extravasate to different organs of which only a small fraction will 
develop into metastasis. The presence of CTC enumerated with the CellSearch system is 
associated with a relative short survival and their continued presence after the first cycles 
of therapy indicates a futile therapy in patients with metastatic carcinomas. Detailed 
characterization of CTC holds the promise to enable the choice of the optimal therapy for 
the individual patients during the course of the disease. The phenotype, physical and 
biological properties are however not well understood making it difficult to assess the 
merit of recent technological advancements to improve upon the capture of CTC or to 
evaluate their metastatic potential. Here we will discuss the recent advances in the 
classification of CTC captured by the CellSearch system, the implications of their features 
and numbers. Latest capture platforms are reviewed and placed in the light of technology 
improvements needed to detect CTC. Physical properties, phenotype, viability and 
proliferative potential and means to assess their proliferation and metastatic capacity will 
be summarized and placed in the context of the latest CTC capture platforms. 
Keywords: circulating tumor cells; image analysis; filtration; EpCAM; cancer stem cell; 
tumorogenesis 
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1. Introduction 
Circulating tumor cells (CTC) detach from tumors and enter the blood stream, eventually forming 
new metastasis at distant sites [1]. Their frequency is related with progression-free and overall survival 
in breast [2], colorectal [3], castration-resistant prostate [4], small [5,6] and non-small cell lung cancer 
(NSCLC) patients [7]. Availability of a sufficient number of tumor cells offers the opportunity to 
evaluate the presence of treatment targets and as such CTC can be used as a “liquid biopsy”. In breast 
cancer, CTC are a better way to predict therapy success than imaging techniques [8] and compared to 
locally collected tumor samples, they might better represent the tumor progression as these are the 
evading cancer cells. Furthermore, a blood sample analysis is faster, easier and less invasive than 
collecting a tissue biopsy. CTC are however extremely rare, with a frequency of typically 1–10 CTC 
among 6 × 106 leukocytes, 2 × 108 platelets and 4 × 109 erythrocytes per mL of blood [9,10]. This low 
frequency creates tremendous technological challenges for their detection. Currently, the only FDA 
cleared system for CTC detection is the CellSearch system (Veridex, LLC, Raritan, NJ, USA). Recent 
reports describe the development of new CTC capture platforms [11–17] demonstrating an expanding 
interest in this field and attempting to circumvent the limitations of CellSearch. In this review we will 
provide an overview of recent CTC capture platforms, their associated CTC definition and discuss in 
more detail filtration based CTC enrichment, since the majority of others has been extensively 
reviewed elsewhere [18–21]. In the second part of this review we will address the current knowledge 
on CTC biological properties, with emphasis on viability, proliferative capacities and stem-cell like 
properties and finally we will discuss current strategies for CTC culturing. 
2. CTC Definitions and Capture 
The current CellSearch CTC definition comprises an object that stains positively for cytokeratins 
(CKs) 8, 18 and 19, does not stain for CD45, has a nucleus (positive 4',6-diamidino-2-phenylindole 
(DAPI) staining), is more than 4 × 4 μm2 in size and possesses a cell like morphology [9]. However, 
the lack of “one” CTC definition among different technologies raises the questions of (i) what are 
CTC, (ii) how to define them and (iii) what are the absolute minimum requirements of a new 
technology for users to safely rely on its ability to capture CTC? Table 1 summarizes technologies for 
CTC detection split over 3 sub-tables, each one comprising a different capturing method, based on 
physical-, biological- and both physical and biological-CTC properties. Columns 1 to 6 identify the 
parameters used for CTC identification (and intrinsically defining a CTC) and columns 7 to 10 provide 
information over the assay. Table 1 does not provide an exhaustive overview of all parameters used for 
CTC identification and definition in each case, but rather illustrates the discrepancies that exist among 
different technologies regarding the most common parameters. For this purpose, we analyzed whether 
the authors specifically stated to have considered expression of EpCAM (either to capture or stain after 
capturing), CKs, CD45, as well as presence of nucleus, specific morphology and size range. In some 
studies, some of these parameters were mentioned as having been tested, but it was not clear to which 
extend they were accounted for in the definition, being marked in the Table as NC (not clear). 
Following assay parameters were analyzed: numerical aperture of the microscope if CTC identification 
was image-based; inclusion of blind users to score objects as CTC (marked as blind); use of a 
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threshold (or cut off value), which refers to maximum number of positive objects that are identified as 
CTC but not sufficient to account for a positive sample, and inclusion of healthy volunteers to test the 
identification method in parallel with the patient samples. For instance, whereas the CellSearch and 
HB-Chip require positive Epithelial Cell Adhesion Molecule (EpCAM), CKs and nuclei staining to 
count a cell as a CTC, the MagSweeper only requires EpCAM. Furthermore morphology is poorly 
accounted for, and decisive criteria such as size and shape, although mentioned in some reports, are not 
always specified. A threshold is often defined based on values obtained from healthy donor samples, 
but to determine it reliably is challenging. In the prospective clinical studies that lead to the FDA 
clearance of CellSearch for metastatic breast [2] and prostate cancer [4] a discrimination between 
patients with favorable CTC (<5/7.5 mL of blood) and unfavorable CTC (>5/7.5 mL of blood) was 
used and for colorectal cancer [3] <3 CTC/7.5 mL and >3 CTC/7.5 mL was made. Although this 
permits a simple discrimination between patients with favorable and unfavorable prognosis in actuality 
the chances for longer survival decreases with increasing CTC load [22,23]. The change from 
unfavorable to favorable CTC after the first cycles of a new therapy is associated with increased 
survival benefit [4,23,24] making CTC an excellent tool to monitor the effectiveness of therapy. 
Question remains what time period is needed to assess a meaningful decrease in CTC and how to judge 
what represents a decrease in CTC especially at low CTC numbers. Guidelines for the interpretation of 
true changes in CTC numbers have been introduced recently [22]. Bottom line however, is that the best 
survival prospects are when zero CTC are detected by the CellSearch system [22].  
Given that only ~70% of breast cancer patients with metastatic disease have 1 or more CTC in 7.5 mL 
of blood it was surprising to see that ~20% of early breast cancer patients before surgical intervention 
had 1 or more CTC in 7.5 to 30 mL of blood and that the presence of CTC was associated with a 
significant increase in the risk of recurrence and shorter overall survival [25–28]. The sensitivity and 
specificity of the technology for CTC detection will need to be significantly improved before it can be 
reliably introduced in the early cancer disease setting. Application of a metastatic cascade model to 
women with breast cancer suggests that recurrence of breast cancer could be reduced from the current 
9% to 1% when a CTC concentration of 9 CTC/L blood could be reliably detected [29]. Analysis of 
larger blood volume can be achieved through leukapheresis and a recent report indeed showed a larger 
number of CTC as well as a larger proportion of patients in which CTC are detected by passing 
leukapheresis products through a CellSearch system [30]. 
2.1. Automated Identification of CTC 
CTC identification remains a manual process executed by trained operators. It is laborious, time 
consuming and highly subjective. Automated identification by image analysis algorithms would be a 
more suitable approach, as it eliminates the subjectivity, makes the assignment of objects as CTC 
highly reproducible and is fast. The caveat of automated image recognition of cells is that the images 
need to be acquired on the same or on very similar platforms. Differences in numerical aperture of the 
objective, illumination, fluorescent filters, camera characteristics and integration time used for each of 
the fluorochromes will have a large influence on the reported results. The algorithms developed for the 
CellSearch system therefore likely will not be applicable to other systems and quantitative morphological 
and immunological features of the CTC can only serve as a rough guideline for alternative systems.
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Table 1. Overview of published CTC isolation technologies comparing parameters used for CTC definition and identification. Only 
technologies already tested with patient samples were included. The most common parameters were compared across publications, but in 
some cases other parameters not specified in the table heading were considered in the original publication. For more details about each 
column, please see main text. As an example, the first entry of the table should read: CTC definition was size based and none of the other 
specified parameters were taken into account; CTC objects were not identified using images therefore numerical aperture is not an applicable 
parameter in this case, the assay did not include blind users and it did not include a threshold number for CTC positive objects. 
Technology 
CTC Definition Assay Parameters  
EpCAM CKs CD45 Nucleus Morphology Size Num Aperture Blind Threshold Healthy Donors Ref 
Capture by physical properties 
Label-free DC Impedance Based  
Microcytometer 
− − − − − + NA − − + [13] 
Microtube Device + − − - − − NM − − + [31] 
ISET − NC − NC NC − NM − − + [32] 
Filter Based Microdevice − + − NC NC − NM − − + [33] 
Capture by immunological properties 
CellSearch + + + + + + M + + + [9] 
CTC-chip + + + NC NC NC NM + − + [34] 
HB-Chip + NC + NC NC NC NM + + + [35] 
MagSweeper + − − − − − NM − − + [36] 
Capture by physical and immunological properties 
GEDI-CTC − − + + + − M + − + [37] 
posCTC-iChip + + + + − − NM − + + [12] 
+/−: applied/not applied to definition or assay parameter; NA: not applicable; M: mentioned; NM: not mentioned; NC: not clear. 
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Recently algorithms for automated identification of CTC were developed using stored images from 
samples from castrate resistant prostate cancer (CRPC) patients processed with the CellSearch  
system [38]. The image analysis algorithm identified potential CTC by object segmentation in the 
cytokeratin (CK) image and measured various properties of the object. Next, it automatically detected 
four independent features (size, CK-PE, CD45-APC and DNA-DAPI intensity) on the identified 
objects with the highest impact on Cox Hazard ratio (HR) of patient survival data. With these features, 
the algorithm created different classifiers by varying the inclusion criteria of the four different features. 
The results of each classifier were compared to those of manual identification and within the data set 
tested, many classifiers provided comparable HR for both baseline and follow up samples as the 
manual CellSearch CTC identification [38]. The optimal classifier (CK-PE > 50 counts, DAPI ≤ 170 
counts, CD45-APC < 60 counts and size between 34–224 µm2) was then verified with an independent 
data set of CRPC patients, which again resulted in comparable HR as the manual CTC count, being, to 
the best of our knowledge, the first automated algorithm to reliably count CTC. In addition, using 
images from breast, colorectal and prostate cancer patients, manual and automated counting resulted in 
similar prognostic value for both methods. However, when limiting automated identification solely to 
morphological features of CTC, CTC size and nuclear-to-cytokeratin ratio had significant impact on 
survival for breast cancer patients, but not in the case of colorectal or prostate cancer patients [39].  
The automated algorithm approach was also used to verify whether different CTC definitions could 
result in more significant CTC changes between baseline and follow up CTC counts. Four different 
automated CTC definitions and the manual one were compared for HR results among a set of 
CellSearch images from breast and prostate cancer patient CellSearch samples. Even with looser CTC 
definitions, both Overall Survival and Progression Free Survival were similar. Although looser CTC 
definitions might reduce the Poisson error associated with the sampling noise, they also include more 
false positives, which offsets the effect. Ultimately, the increase of the sample volume is needed to 
reduce the Poisson error [10,29,30]. Filtration based technologies can cope with larger sample volumes 
and in addition, explore size based differences between cells of interest and background cells. This 
would offer an alternative to enrichment strategies based on EpCAM, widely accepted as capturing 
molecule (Table 1), but described to be down regulated during Epithelial to Mesenchymal Transition 
(EMT) or in some cases not expressed at all. The next sections will further discuss CTC EpCAM 
expression and the requisites of filtration-based technologies as a suitable approach for detecting 
EpCAM− CTC. 
2.2. EpCAM+/EpCAM− CTC  
Relying on antigen expression to capture CTC implies that cells not expressing the antigen of 
interest will be missed. Giving the biologically heterogeneity of cells within a tumor, the density of 
any antigen will vary. This heterogeneity is also observed in CTC and as such it is expected that not all 
CTC will be captured in case only one antigen is targeted. The EpCAM antigen has been the prime 
choice target molecule in many of the technologies developed for CTC capture [2,12,34–37]. EpCAM 
is expressed to various degrees by many epithelial cancers, but not by all [40–45]. In renal cell cancer 
EpCAM expression is for example rare whereas in breast cancer the expression can be very 
heterogeneous. Moreover, down regulation of EpCAM is required for cancer cell invasion, which takes 
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place during EMT [46], a process via which epithelial cells gain mesenchymal characteristics that 
empowers them to metastasize [47]. EMT-like changes have been reported on CTC as well [48–50]. 
Cytokeratin negative CTC from breast cancer patients have been described to express the EMT related 
antigens vimentin and fibronectin [51] and breast cancer patients negative for hormone receptors, high 
tumor grade, triple-negative disease or inflammatory breast cancer had increased probabilities for 
being undetectable by CellSearch, possibly due to CTC undergoing EMT [52]. In particular it was 
shown that the CellSearch did not detect normal-like breast cancer cells from cell lines [53] but 
combining CellSearch enrichment step with CD146 improved detection rates of breast cancer cell  
lines [54], as well as adding anti-CD49f to the immunostaining cocktail [55]. These data suggest that 
EpCAM+/EpCAM− nature of metastasizing cells should be considered when designing CTC  
capture technologies. 
2.3. Filtration-Based Technologies 
Separation of tumor cells from blood cells by filtration has been described quite some time  
ago [56], more recently several commercial systems have become available for CTC enrichment by 
filtration [32,57,58]. Comparison of the sizes of leukocytes and CTC showed an average leukocyte 
diameter of about 8.1 μm, whereas CTC were usually larger, with an average size of 10.7 μm in the 
case of prostate cancer, 11 μm in colorectal cancer and 13.1 μm in breast cancer [14,39]. This 
difference in size indeed can be explored by technologies based on filtration. However, CTC recovery 
is not exclusively dependent on cell size, but also dependent on deformability and nucleus size [14]. 
Furthermore, fixation, for instance, increases the apparent viscosity of a cell which increases the 
pressure needed to pass a cell through the same pore size [59]. Also different fixatives will impact 
apparent viscosity differently: paraformaldehyde is a stronger fixative compared to CellSave (the 
proprietary fixative in ethylenediaminetetraacetic acid (EDTA) blood draw tubes used in combination 
with CellSearch), therefore recovery of paraformaldehyde fixed cells is lower than cells collected and 
fixed in CellSave tubes [59]. Furthermore, some fixatives result in the formation of precipitates, which 
in the case of blood will yield large aggregates of serum proteins and if used in combination with 
filters, will result in clogging [32]. Filters should also possess a set of characteristics that make them 
usable for these systems. For instance, track etch filters do not have a flat surface making the imaging 
process very difficult. On the other hand, TEM grids proved to be too porous and it was not possible to 
distinguish adjacent cells from each other [14]. Therefore filter requisites should include (i) no-reactivity 
with the sample (ii) maintenance of planar form during filtration and imaging and (iii) pores 
sufficiently separated to facilitate discrimination of cells. Regarding the number of pores, surprisingly, 
this is important in terms of leukocyte retention, but not important for CTC recovery, as long as the 
number of pores is at least equal to the number of CTC present in the sample. However the smaller the 
pore size, the higher the pressure needed to filter. All experiments should be conducted at a pressure 
lower than the critical pressure of CTC, to prevent CTC to be pulled in through the pores. 
Filtration based technologies have been tested with patient blood samples diagnosed with different 
types of metastatic cancers and proved valuable. For instance, using polycarbonate track etch 
membranes with 8 µm sized pores it was possible to recover tumor liver cells from hepatocellular 
carcinoma patients, while healthy volunteers and chronic hepatitis patients scored negative [33]. In 
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Systematic evaluation of blood samples from patients with different carcinomas will teach which 
CTC are present and by following the patients we can learn what the relevance is of the various CTC 
subpopulations. Still with this approach we will not know whether any smaller EpCAM− CTC were 
present in the samples. To answer these questions, only a better understanding of CTC biology can 
help us tuning technologies to capture a real CTC, by integrating a reliable CTC definition with  
the technology. 
3. Biological Properties of CTC  
Morphology of CTC within and between patients is very heterogeneous [9,31,63,64] suggesting also 
extensive differences in their biological properties. Although many CTC are shed from the tumor(s) into 
the circulation, only a few will survive, successfully colonize in distant organs, promote the formation of 
blood vessels and consequently develop into new metastasis. The viability and proliferative state of these 
cells will determine to a great extent whether they have the ability to succeed. 
3.1. Viability 
An example of the aforementioned intra-patient heterogeneity is illustrated in Figure 2 panels A, B 
and C. Panel A shows a cluster of three large tumor cells that appear quite healthy and raises the 
question how they could have passed the peripheral vascular bed. Panel B shows six “intact” tumor 
cells varying in size and shape and panel C shows six “damaged” CTC varying in size and showing a 
distinct punctuation of the CK staining. These observations lead the hypothesis that these cells were 
undergoing apoptosis. This indeed appeared to be the case as this distinct cytokeratin pattern was 
associated with the presence of the M30 epitope present only on caspase-cleaved CK18 [64,65]. This is 
illustrated in panel D for three cells with punctuated CK: the panels on the left show the overlay of the 
CKs 8, 18, 19 FITC (green) and nucleus (purple) and the black and white images on the right the M30 
staining showing the presence of the M30 epitope in these “CK containing granules”. In contrast with 
M30, the expression of the anti-apoptotic B-cell lymphoma protein 2 (bcl-2) suggest a viable cell 
resistant to apoptosis and its expression might also predict response to selected endocrine and 
chemotherapies [66,67]. In panel E images of bcl-2 expression of CTC is shown: on top two CTC of a 
breast cancer patient are shown, one of them expressing bcl-2 whereas the other does not. The image in 
the middle shows a CTC clearly staining with bcl-2 whereas the bottom images show a CTC that is not 
expressing bcl-2. The expression of M30 and bcl-2 in CTC is quite heterogeneous and whether or not 
this has any clinical utility has yet to be determined [68]. 
Analysis of M30 expression in CTC from 10 prostate cancer patients showed remarkable intra and 
inter-patient variability [66]. The intact proportion of CTC among patients ranged from 3% to 76% and 
the majority of CTC events were classified as CTC fragments [66]. In another study, among 102 Small 
Cell Lung Cancer (SCLC) patients, apoptotic CTC were detected in 44 (43%) and their proportion to 
intact CTC varied from 0.2% to 20% [6]. Among hepatocellular carcinoma though, the incidence of 
patients with apoptotic CTC was 23% and the ratio of apoptotic CTC to total CTC number was  
8.3% [69], lower when compared to other studies [65,66,70–72]. Interestingly, within clustered CTC 
(termed as circulating tumor microemboli, CTM) none of the cells presented an apoptotic nuclear 
morphology and moreover, bcl-2 was detected in CTC and CTM in 18 of 30 patients [6]. In contrast to 
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these values, the mean viability of the CTC-chip (Table 1) captured cells was approximately 98%, 
determined by assessing cell membrane integrity in four samples obtained from lung and prostate 
cancer patients [34]. Also recently, Kallergi et al. reported higher incidence of apoptotic CTC in early 
breast cancer patients than in metastatic ones and although the numbers of apoptotic CTC were 
reduced after treatment, no statistical data was presented on the later results [73]. Numbers of apoptotic 
disseminated tumor cells (DTC) in the bone marrow were also higher in breast cancer patients with 
stable or remissive disease than in the patients with progressive disease, 3 to 4 weeks after therapy, but 
a comparison between these and values before therapy (basal) among the three groups of patients was 
not presented, but still suggesting that high M30 levels might be associated with a favorable response 
to therapy [74]. On the contrary, the mean values of M30 blood serum levels were elevated in lung 
cancer patients, consistently at 24 and 48 hours after chemotherapy. Moreover elevated basal levels of 
M30 were associated with increased risk of death [75]. 
Figure 2. CTC heterogeneity. In all panels except for F, green represents CKs 8, 18 and 19 
and purple the nuclear staining. (A) Cluster of three large CTC; (B) Individual CTC 
varying in size and shape; (C) CTC varying in size and shape exhibiting distinct punctuation 
of the CK staining; (D) CTC stained for CKs and nuclei (left) and staining of cleaved 
CK18 identified through M30 staining (right). Note the association between the punctuated 
CK staining and the M30 staining; (E) CTC stained for CKs and nuclei (left) and bcl-2 
staining (right). Notice that only one of the CTC on the top row exhibits punctuated CK 
staining; (F) Left column showing overlay of CTC from a melanoma patient, staining of 
HMW-MAA (green) and nuclei (purple) and on the right column Ki67 staining. 
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Besides lacking a common message, the studies mentioned above also rely on different methods to 
measure apoptosis, stressing the need for more controlled studies to ascertain the clinical utility of 
apoptotic CTC. Nonetheless we can be sure that apoptotic CTC will not be able to form distant 
metastasis and the ability to extract information is reduced as for example no fluorescence in-situ 
hybridization can be performed on these cells [76]. Still their presence is associated with poor 
prognosis and as the frequency of these apoptotic cells and bodies can be substantially higher they may 
be used to monitor therapy [63]. 
3.2. Proliferative Capacity 
The potential of a CTC to proliferate is a requisite for their ability to colonize in distant organs. 
Panel F of Figure 2 shows CTC in a melanoma patient captured by expression of CD146 and stained 
for anti-high molecular weight melanoma-associated antigen (HMW-MAA). HMW-MAA is expressed 
in a large percentage of melanoma lesions with restricted distribution in normal tissue [77]. The image 
at the top shows a CTC expressing Ki67, an universally expressed antigen in proliferating cells but 
absent in quiescent ones [78]. The CTC in the middle image is clearly in the midst of cell division and 
verified by its Ki67 staining of both nuclei. The CTC of the same patient in the bottom image does not 
stain with Ki67 illustrating the diversity of proliferating stages of CTC. Reports on Ki67 expression in 
nine breast cancer patients with CTC showed that none of the CTC expressed Ki67 [79] whereas in 
another study ~25% of the CTC in breast cancer patients expressed Ki67 [73]. In SCLC patients both 
apoptotic and proliferating CTC were detected, but confined to the solitary cells and not detected in the 
tumor microemboli CTM [5]. The number of reports describing the apoptotic and proliferative status 
of CTC are still too scarce to make definitive statements and what, if any, effect does therapy have on 
the proliferative state of CTC surely will need further investigation. 
3.3. Stem Cell-like Properties 
Whereas viability and proliferative state of CTC will partially determine their capacity to 
successfully extravasate and form metastasis, other identity traits are crucial to the process also. It has 
been proposed that CTC contain the tumor stem cells disseminated from the primary tumor to the 
distant metastatic sites [80]. This is supported by the fact that within human breast cancer primary 
tumors, a subpopulation of cells expressing CD44+CD24−/low, having stem cell characteristics, were 
able to form tumors when only 200 of these cells were implanted in non-obese diabetic/severe 
combined immunodeficient (NOD/SCID) mice [81]. However tumors did not form when 20,000 cells 
isolated from the same tumor but not expressing the CD44+CD24−/low phenotype were implanted in the 
mice. Furthermore, this subpopulation expressed the stem cell marker Oct-4 when cultured in vitro [82]. 
Also among DTC detected in the bone marrow of early breast cancer patients, 72% expressed the 
putative stem cell phenotype, CD44+CD24− [83].  
Studies with CTC revealed subpopulations with stem cell-like phenotypes. In a study comprising 30 
metastatic breast cancer patients, it was shown that 80% of the patients had the CK+/CD44+/CD24−/low 
phenotype among their CTC and the mean prevalence per patient was 35.3% [84]. The authors also 
observed the existence of a less common observed population of aldehyde dehydrogenase 1 
(ALDH1)high/CD24−/low. ALDH1 has been associated with poor prognosis in different forms of breast 
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cancer [85,86] and it has been shown that both normal and malignant stem and progenitor cells display 
high ALDH activity [87–89]. Therefore, the ALDH1 expressing CTC among the CD24−/low phenotype 
may further distinguish a subpopulation of higher metastatic potential. Accordingly, breast cancer cells 
displaying high ALDH activity and the CD44+CD24− phenotype were highly tumorogenic compared 
to cells that did not display the CD44+CD24− pattern [81]. 
Recently CTC were identified in blood samples of 82 hepatocellular carcinoma patients in a cohort 
consisting of 123 [69]. EpCAM+ CTC were isolated using the CellSearch profile kit, cytospined and 
immunostained for stem cell-like markers according to a random separation of the blood samples for 
different stainings. CTC were found positive for stem cell-like markers such as CD133, ATP-binding 
cassette sub-family G member 2 (ABCG2) and β-catenin. However, none of the CTC was positive for 
CD90, at least in the group assigned to that staining. It would be interesting to know the separate 
tumorogenic potential of these CTC subpopulations, as it was shown for cells from primary tumors. 
For instance, CD133+ cells isolated from human brain tumors were capable of initiating tumor 
formation in NOD/SCID mouse brains whereas the CD133− fraction could not, even when a thousand 
times more cells were implanted [90]. Moreover co-expression of CD133 and ALDH1A1 in surgically 
resected lung tumors of early stage NSCLC patients was strongly associated with poor survival [91]. 
Major signalling pathways that characterize normal stem cells were found activated in tumor cells 
and CTC as well. CTC from patients with primary and metastatic breast cancer were shown to express 
receptors and activated signalling kinases of the EGFR/HER2/P13K/Akt pathway [92]. The authors 
analyzed peripheral blood mononuclear cells (PBMC) from 32 early and 16 metastatic breast cancer 
patients and reported that phospho PI3K/Akt were identified in a significant proportion of CTC. The 
pathway PTEN/Akt/mTOR has been described as one of the major pathways in the regulation of 
mammary stem/progenitor cells and to play a central role in the viability and maintenance of cancer 
stem cells in breast, promoting proliferation and the inhibition of apoptosis [93,94]. 
CTC with stem-cell like traits might represent a more aggressive subset of CTC. However, the 
clinical utility of stem cell-like phenotypes needs further investigation. Regarding ALDH1 for 
instance, it was still not possible to associate ALDH1 positivity with any of the studied 
clinopathological factors [95], although within the group of patients with CTC 46% displayed the 
ALDH1+ phenotype against 5% of the patients without CTC. In another study, it was not feasible to 
evaluate the clinical relevance of the expression of CD44+CD24− or ALDH1highCD24−/low phenotype 
among CTC due to the heterogeneity of the study patients population [84], again claiming the need for 
more controlled studies. 
4. CTC in Vitro Culturing and in Vivo Models 
The ability to expand CTC will greatly enhance the ability to study the metastatic process, explore 
new drugs with anti-tumor activity and test the anti-drug or drug combination that is most suitable to 
treat the individual patient. 
4.1. CTC in Vitro culturing 
CTC in vitro culture requires the cells to be viable after extraction from the blood. However most 
technologies depend on intracellular staining (e.g., CKs), which implies loss of cellular viability due to 
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fixation and permeabilization methods. Some authors have presented solutions that preserve cell 
viability, generally at the cost of diminishing the number of molecular targets, which compromises 
isolation of a more heterogeneous CTC population and at the risk of isolating more hematopoietic 
cells. Though only tested on cancer cell lines, Takao and Takeda [96] developed a potential protocol 
for CTC enumeration consisting of a flow cytometer using a disposable microfluidic chip that allows 
sample collectability afterwards. The cancer cells (PC-9 and MCF-7) were isolated from whole blood 
with EpCAM-microbeads and isolated fractions labeled with an antibody targeting a different EpCAM 
epitope, anti-CD45, Syto9 and PI dyes (live/dead staining). They successfully gated live cancer cells. 
Repeating this protocol without the blood mixing step allowed for captured MCF-7 and PC-9 to be 
collected from the outlet reservoir of the chip and transferred to the culture dish with standard culture 
medium where they grew normally, demonstrating that the procedure is non-cytotoxic and enables 
capturing of live cells. However, this procedure was so far tested only with cell lines and the starting 
amount of cells was very high (5,000 cells), compared to patient samples that might bare a few CTC 
only. In those cases collection of cells from the chip will be more challenging, therefore a strategy 
involving less manipulation is preferable. More recently microchip assays have provided a combined 
capture and in situ cell growth solution. A microstructured polydimethylsiloxane (PDMS) chip 
containing round pillars functionalized with anti-EpCAM was tested for its capturing efficiency with 
PC3-9 cells spiked in blood and stably expressing mCherry fluorescent protein [97]. After capture, 
cells were encapsulated in the chip by injecting a polyethylene glycol (PEG) precursor that jellified 
inside the chip, encapsulating the cells in a three-dimensional (3D) protective environment. Afterwards, 
the PDMS chip containing the hydrogel and supportive glass were transferred to a Petri dish for cell 
culture under standard conditions. After six days, 17% of the transferred cells were alive and spheroids 
of about 50 μm could be observed on the chip, sustaining that the method allows manipulation of live 
cells from microchip to standard culture dishes and supports tumor-like cell growth. A schematic of 
this microfluidic chip is depicted in Figure 3, including the experimental procedure of sample loading, 
hydrogel encapsulation and cell growth on petri dish. 
Another microfluidic device demonstrated suitability for collection of isolated cells from mice 
bearing tumors and their subsequent culturing for at least four passages [98]. 4T1 mouse mammary 
cells were implanted subcutaneously in Balb/c mice and after 2–4 weeks mice were sacrificed and 
whole blood collected. Blood was mixed with anti-EpCAM coated magnetic beads, passed through the 
microfluidic device and isolated cells were directed to the outlet channel by shifting the position of the 
magnet. Collected cells were plated in 96 well culture dishes, with standard culture medium. They 
grew normally and remained viable throughout the entire culturing period. However the identity of 
these cells was not clearly established, as the only enrichment molecule used was EpCAM and no clear 
evidence of a “CTC only” culture was given. The issue of CTC culture purity was, however, 
considered by Hughes and coworkers [62]. In this study, buffy coats from breast, prostate, lung and 
ovarian cancer patients were flown through a polyurethane microtube, functionalized with Protein G, 
E-selectin fused to IgG and anti-EpCAM or anti-prostate specific membrane antigen (PSMA) (only for 
prostate) antibodies. Bound cells were eluted with accutase and transferred to 1 well of a 96 well plate 
where they grew for 5 days, when they were analyzed for purity. CTC were defined as EpCAM+ or 
PSMA+, DAPI+ and having 10–25 µm in diameter cells. Purity, the ratio of CTC positive cells per 
DAPI+ cells, was on average 66% and 37.2%, depending on whether the microtube had been pre-coated 
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before functionalization with halloysite nanotubes or not, respectively. Culture purity is essential to 
understand the identity of the captured population to confidently perform characterization assays and 
anti-tumor drug tests. As purity was only established 5 days after culturing, it could also be the case 
that culturing conditions enhanced proliferation of EpCAM− or EpCAM+ cells and the purity ratios 
immediately after capture were higher or lower than the ones presented in the article. This would be 
important to know in order to optimize and adjust culturing conditions that favor the growth of CTC 
rather than non-CTC cells in the culture dish. 
Figure 3. Proposed microfluidic setup by Bichsel et al. [97] that allows cancer cells to be 
transferred from a capturing microchip device to a cell culture dish. (A) Microfluidic setup 
with transparent cover (1), cover with inlet and outlet tubing (2), microstructured PDMS on 
a glass slide (3) and metal support frame (4); (B) Detail of the microstructured PDMS 
geometry containing pillars of 100 µm in diameter; (C) PDMS functionalization principle; 
(D) Schematic of sample loading in the microfluidic device and magnification of a  
pillar-bound cell, followed by injection of the hydrogel precursor that solidifies and 
encapsulates the cells. Gel-encapsulated cells are finally transferred to cell culture 
conditions to be grown. Reproduced from [97] with permission from The Royal Society of 
Chemistry. For more details, the reader is referred to the original publication.  
 
Besides microfluidic devices, there is proof of principle that filter based technologies are suitable 
for culturing CTC [99]. Blood derived from tumor bearing mice was filtered through two sandwiched 
parylene membranes containing pore sizes of 30 µm and 8 µm (top and bottom membrane 
respectively) spaced by a gap of 5.4 µm. Since CTC are bigger than the remaining cells found in the 
blood, in principle CTC will be retained by the bottom filter while unwanted cells will be filtered out. 
After filtration the bottom filter was transferred to a culture dish with cell growth media and the culture 
was maintained for at least 21 days. Although the purity of the captured and the grown cells still needs 
to be demonstrated, it showed that such membranes are capable of maintaining cell viability and 
supporting cell growth under appropriate cell culturing conditions. 
In the studies mentioned so far, either tumor cell lines were used, for which optimal culture media 
formulations have been long established or high starting numbers of primary cells isolated from blood. 
However, one of the major challenges in culturing CTC will be when the patient isolated fraction is 
A 
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reduced to a few cells. Assuming they are viable and capable of proliferating, still their clonogenic 
potential must be assured by the right cocktail of growth factors and perhaps even a different substrate 
than the bottom of a culture dish. Recently, Zhang and coworkers used stem cell culture medium for 
cell growth of CD45−/ALDH1+ isolated cells from PBMC of breast cancer patients [100]. EpCAM+ 
cultures derived from the initial population did not survive beyond 14 days, however EpCAM− 
colonies did and were further expanded in medium for epithelial cells. Out of these cultures, 3 cell 
lines were established. This is, to the best of our knowledge, the first report on the generation of CTC 
cell lines. Further characterization of these cell lines showed expression of several tumor-initiating 
markers, such as EMT, CKs and stemness. The use of different media possibly provided a necessary 
transition phase between the state of suspension in blood and culture in the dish. 
Some in vitro models have added a dynamic dimension to the study of metastasizing cells [101–104]. 
For instance, a microfluidic device was designed to study the interaction between circulating cancer 
cells and endothelia during the mechanism of extravasation. The authors devised a system in which a 
chemokyne known to attract cancer cells (CXCL12) is applied onto the basal side of the endothelia. 
Cancer cells flow than on the apical part (MDAMB-231). They found out that treatment with that 
chemokine enhances adhesion of cancer cells to endothelia through expression of CXCR4 on the 
endhothelia independent of the expression of CXCR4 or CXCR7 on the cancer cells [101]. Such “lab 
on a chip” models permit the understanding of specific interactions that static in vitro cultures don’t. 
However, currently only animal models can provide a global physiological response to different study 
parameters, including drug response. In the next section, we will elaborate on the current existent  
in vivo models to study CTC. 
4.2. CTC in Vivo Assays Using Mouse Models 
CTC collected from patients can provide valuable information about their biology, and if successful 
cultured in vitro, serve as basis for anti-tumor drug screening. However, animal models can add on the 
dynamics of metastasis and drug response at a physiological level. Using in vivo flow cytometry it was 
possible to track fluorescently labeled cancer cell lines when injected intravenously in mice [105]. 
Another study used an orthotopic cancer mouse model, instead of intravenous injection of cancer cells, 
by implanting tumor tissue derived from a green fluorescent protein (GFP)-expressing hepatocellular 
carcinoma cell line in the liver of mice [106]. CTC flow was monitored through an artery in the mouse 
ear and provided evidence that the number of CTC and distant early metastasis decrease after tumor 
resection. More recently, and in line with these data, CTC shedding into the bloodstream was 
monitored using tumor subcutaneous mouse model and Photoaccustic Flow Cytometry, a method 
combining the detection of laser-induced acoustic waves and fluorescence [107]. These experiments 
provided pre-clinical evidence that standard medical practices involving tumor manipulation, such as 
palpation during physical examination, incisional biopsy and laser therapy, enhance penetration of 
CTC into the bloodstream. They implanted mouse melanoma and mouse breast cancer cells, 
constitutively expressing GFP, in the subcutis of the mice ear or on their back. Once the tumor had 
developed, before, during and after manipulation they monitored the veins in the ear for acoustic 
waves or fluorescent signals. CTC signals were considered those above red blood cells (RBC) 
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background, since leukocytes and endothelial cells provide low fluorescence compared to the GFP+ 
cancer cells or RBC.  
The functional capacity of potential metastasis inducing cells was tested in mouse models as well. 
PBMC were isolated by density gradient centrifugation using Ficoll-Paque PLUS medium and sorted 
via magnetic beads to enrich for EpCAM−/CD45− and EpCAM+/CD45− [69]. Injecting 300 of the 
EpCAM+/CD45− cells in NOD/SCID mice induced tumor formation in 50% of the animals, but 
injection of 10,000 EpCAM−/CD45− did not. Further enrichment within the EpCAM+/CD45− fraction, 
could perhaps have resulted in a higher number of animals developing metastasis. Similar strategy, but 
enriching beyond EpCAM/CD45 expression, was followed by Baccelli et al. [108]. The authors 
hypothesized that bone marrow can provide a suitable environment for the engraftment of CTC, 
because it is already a reservoir for DTC. They showed that if at least 1,109 cells acquired after 
depletion of hematopoietic cells from blood of breast cancer patients, were injected in the medular 
cavity of the femur of mice, these animals would developed metastasis in other bones of the skeleton. 
Moreover, CTC, defined as PI−/CD45−/EpCAM+ cells, isolated by FACS after hematopoietic 
depletion, were further analyzed for CD44, CD47 and hepatocyte growth factor receptor (MET) 
expression. Eight months after injection of 6,330 of CD44+/CD47+/MET+/− cells in the medular cavity 
of the femur of mice, bone metastasis developed. Primary tumor, patient bone metastasis and mice 
bone metastasis all expressed MET, which led the authors to hypothesize that metastasis inducing CTC 
are enriched among CD44+/CD47+/MET+ CTC and indeed that subpopulation correlated better with 
disease progression than the bulk CTC. What remains to be understood is whether the injection of such 
large numbers of CTC are within physiological ranges of DTC harbored in the bone marrow  
of patients.  
5. Conclusions 
Technologies for CTC capture explore the properties that distinguish them from the hematopoietic 
background. CTC capture targeting EpCAM, the gold standard so far, will need to be expanded to 
explore the full potential of CTC. Next to CTC capture based on antigen expression, CTC can be 
obtained by either depletion of all the blood components or separation based on differences in physical 
properties. The heterogeneity of antigen expression and physical properties of tumor cells makes it 
quite a challenge to identify the optimal approach for CTC selection and identification. Besides CTC 
enumeration and assessment of their protein and gene expression to monitor and select therapy, 
expansion of CTC could facilitate screening of actual response to anti-tumor drugs and choose the best 
therapeutic agent for each patient. CTC must however be viable and retain their clonogenic potential 
when transferred to the culture dish. In Figure 4, we propose an alternative for CTC enumeration based 
on whole blood inspection, currently being explored by the European consortium CTCTrap [109]. It 
combines immuno-capture and size based separation for CTC enumeration and characterization 
including the ability to culture the CTC. In our view, such approach will provide a more effective and 
complete platform to capture, enumerate and characterize CTC than current technologies and enable 
their detection in all patients with known and unknown metastatic disease.  
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